Adamis Urges Stockholders to Vote to Reelect the Company’s Board of Directors at Upcoming Annual Meeting on Friday, July 16th
13 July 2021 - 10:00PM
Business Wire
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or
the “Company”) today urged its valued stockholders to vote to
reelect all five members of the Company’s Board of Directors (the
“Board”) at the upcoming Annual Meeting of Stockholders (the
“Annual Meeting”) on July 16, 2021. In addition, the Board issued
the following statement:
“Ahead of this year’s Annual Meeting, the Board prioritized
engaging with stockholders and gathering feedback regarding the
Company’s governance, operational priorities and overall strategy.
We very much appreciate that a large cross-section of stockholders
ultimately provided their candid viewpoints to us and our
representatives. The Board is committed to factoring these
important views into its go-forward plans. While the road to value
creation in the biotechnology and pharmaceutical industries is
often bumpy, we firmly believe that Adamis now has tangible
pipeline momentum that can be built on over the next year. The
Board will focus on putting stockholders’ interests first and
making decisions that can position Adamis to become a source of
enduring value for investors, patients, providers and society as a
whole.”
For more information about the Company’s strategic priorities
and high-potential pipeline, please view our updated investor
presentation here.
About Adamis
Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. The
Company’s SYMJEPI (epinephrine) Injection products are approved by
the FDA for use in the emergency treatment of acute allergic
reactions, including anaphylaxis. Adamis’ naloxone injection
product candidate, ZIMHI, for the treatment of opioid overdose is
currently under FDA review. Adamis is developing additional
products, including treatments for acute respiratory diseases, such
as COVID-19, and radiation dermatitis. The company’s subsidiary, US
Compounding Inc. (“USC”), compounds sterile prescription drugs, and
certain nonsterile drugs for human and veterinary use by hospitals,
clinics, surgery centers, and vet clinics throughout most of the
United States. For additional information about Adamis
Pharmaceuticals, please visit www.adamispharmaceuticals.com.
Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include those that express
plans, anticipation, intent, contingencies, goals, targets or
future development and/or otherwise are not statements of
historical fact. These statements relate to future events or future
results of operations, including, but not limited to the following
statements: the Company’s beliefs concerning the safety and
effectiveness of Tempol and the Company’s other product candidates;
the timing of commencement or completion of any studies or trials
relating to Tempol and the availability of funding for studies or
trials; the results of any studies or trials that the Company may
conduct relating to Tempol; the Company’s ability to successfully
commercialize the products and product candidates described in this
press release, itself or through commercialization partners, and
the Company’s beliefs concerning the commercial success of its
products; future regulatory actions relating to the Company’s New
Drug Application (“NDA”) relating to its ZIMHI product; the
Company’s beliefs concerning the benefits, enforceability, and
extent of intellectual property protection afforded by patents and
patent applications that it owns or has licensed and its rights
under applicable license agreements, and its ability to enforce its
patents and other intellectual property rights against third
parties; the Company’s expectations concerning future growth;
expectations and statements about the Company’s strategies,
objectives, future goals and achievements; and other statements
concerning our future operations, activities and financial results.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, which may cause Adamis’
actual results to be materially different from the results
anticipated by such forward-looking statements. There can be no
assurances regarding the outcome of trials or studies relating to
Tempol or that Tempol will be found to be safe and effective in the
treatment of COVID-19 or any other indication. There can be no
assurances that future sales of SYMJEPI will meet our expectations.
There can be no assurances regarding the timing or outcome of the
FDA’s review of our resubmitted NDA relating to ZIMHI, or that the
Company will be able to successfully take any actions or develop
any additional information that the FDA may require in connection
with its review of the resubmitted NDA for ZIMHI. There can be no
assurances that the FDA will consider the Company’s responses
included in the resubmitted NDA relating to ZIMHI as satisfactory,
or that the product will be able to compete successfully in the
market if approved and launched. The Company may not achieve one or
more of the future goals described in the press release either
within the anticipated time periods or at all. In addition, as
previously disclosed, each of the Company and USC previously
received a subpoena from the U.S. Attorney’s Office for the
Southern District of New York issued in connection with a criminal
investigation. Accordingly, all forward-looking statements are
subject to the outcome of this investigation, as well as the
related investigation being conducted by the Company’s Audit
Committee. We cannot assess the impact of each factor on our
business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those
contained in any forward-looking statements. You should not place
undue reliance on any forward-looking statements. Further, any
forward-looking statement speaks only as of the date on which it is
made, and except as may be required by applicable law, we undertake
no obligation to update or release publicly the results of any
revisions to these forward-looking statements or to reflect events
or circumstances arising after the date of this press release.
Certain of these risks and additional risks, uncertainties, and
other factors are described in greater detail in Adamis’ filings
from time to time with the SEC, including its annual report on Form
10-K for the year ended December 31, 2020 and subsequent filings
with the SEC, which Adamis strongly urges you to read and consider,
all of which are available free of charge on the SEC's web site at
http://www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210713005613/en/
Saratoga Proxy Consulting John Ferguson / Ann Marie Mellone,
212-257-1311 jferguson@saratogaproxy.com /
amellone@saratogaproxy.com MKA Greg Marose, 646-386-0091
gmarose@mkacomms.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2024 to May 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From May 2023 to May 2024